
Sanh D. Phu
Examiner (ID: 3516, Phone: (571)272-7857 , Office: P/2647 )
| Most Active Art Unit | 2618 |
| Art Unit(s) | 2647, 2648, 2682, 2618 |
| Total Applications | 1171 |
| Issued Applications | 1006 |
| Pending Applications | 23 |
| Abandoned Applications | 149 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19541778
[patent_doc_number] => 20240358814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/770056
[patent_app_country] => US
[patent_app_date] => 2024-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18021
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18770056
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/770056 | Polynucleotide molecules used for the prevention or treatment of HPV infection related diseases | Jul 10, 2024 | Issued |
Array
(
[id] => 19477484
[patent_doc_number] => 20240325526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => IMMUNE-STIMULATORY COMPOSITIONS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/751098
[patent_app_country] => US
[patent_app_date] => 2024-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751098
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/751098 | IMMUNE-STIMULATORY COMPOSITIONS AND USE THEREOF | Jun 20, 2024 | Pending |
Array
(
[id] => 20108558
[patent_doc_number] => 12359267
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Compositions and methods for amplifying, detecting or quantifying human polyomavirus BK virus
[patent_app_type] => utility
[patent_app_number] => 18/749700
[patent_app_country] => US
[patent_app_date] => 2024-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23884
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18749700
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/749700 | Compositions and methods for amplifying, detecting or quantifying human polyomavirus BK virus | Jun 20, 2024 | Issued |
Array
(
[id] => 20386826
[patent_doc_number] => 12486546
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => Compositions and methods for amplifying, detecting or quantifying human polyomavirus BK virus
[patent_app_type] => utility
[patent_app_number] => 18/749697
[patent_app_country] => US
[patent_app_date] => 2024-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23842
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18749697
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/749697 | Compositions and methods for amplifying, detecting or quantifying human polyomavirus BK virus | Jun 20, 2024 | Issued |
Array
(
[id] => 20729117
[patent_doc_number] => 12636361
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-26
[patent_title] => Smallpox vaccine for cancer treatment
[patent_app_type] => utility
[patent_app_number] => 18/743581
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 5512
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743581
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743581 | Smallpox vaccine for cancer treatment | Jun 13, 2024 | Issued |
Array
(
[id] => 19615008
[patent_doc_number] => 20240400688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST
[patent_app_type] => utility
[patent_app_number] => 18/734979
[patent_app_country] => US
[patent_app_date] => 2024-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10703
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734979
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/734979 | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST | Jun 4, 2024 | Pending |
Array
(
[id] => 19658863
[patent_doc_number] => 20240425928
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => CANCER VACCINES FOR COLORECTAL CANCER
[patent_app_type] => utility
[patent_app_number] => 18/672637
[patent_app_country] => US
[patent_app_date] => 2024-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30434
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18672637
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/672637 | CANCER VACCINES FOR COLORECTAL CANCER | May 22, 2024 | Pending |
Array
(
[id] => 19432867
[patent_doc_number] => 20240301365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => ONCOLYTIC VIRUS STRAIN
[patent_app_type] => utility
[patent_app_number] => 18/670296
[patent_app_country] => US
[patent_app_date] => 2024-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16471
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670296
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/670296 | Oncolytic virus strain | May 20, 2024 | Issued |
Array
(
[id] => 19417397
[patent_doc_number] => 20240293520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => Antigenic Peptides For Prevention And Treatment Of Cancer
[patent_app_type] => utility
[patent_app_number] => 18/654304
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654304
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/654304 | Antigenic Peptides For Prevention And Treatment Of Cancer | May 2, 2024 | Pending |
Array
(
[id] => 19359364
[patent_doc_number] => 20240261398
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => ADJUVANT AND VACCINE CONTAINING ADJUVANT
[patent_app_type] => utility
[patent_app_number] => 18/634012
[patent_app_country] => US
[patent_app_date] => 2024-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9034
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634012
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/634012 | ADJUVANT AND VACCINE CONTAINING ADJUVANT | Apr 11, 2024 | Abandoned |
Array
(
[id] => 19599593
[patent_doc_number] => 20240390473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES
[patent_app_type] => utility
[patent_app_number] => 18/621631
[patent_app_country] => US
[patent_app_date] => 2024-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25752
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621631
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/621631 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | Mar 28, 2024 | Abandoned |
Array
(
[id] => 19585026
[patent_doc_number] => 20240382583
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/609504
[patent_app_country] => US
[patent_app_date] => 2024-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18609504
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/609504 | HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS | Mar 18, 2024 | Pending |
Array
(
[id] => 20256129
[patent_doc_number] => 12428472
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Human immunodeficiency virus neutralizing antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/597018
[patent_app_country] => US
[patent_app_date] => 2024-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 20
[patent_no_of_words] => 25189
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597018
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/597018 | Human immunodeficiency virus neutralizing antibodies and methods of use thereof | Mar 5, 2024 | Issued |
Array
(
[id] => 20242122
[patent_doc_number] => 12422434
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Systems and processes to screen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 2019 (COVID-19)
[patent_app_type] => utility
[patent_app_number] => 18/441086
[patent_app_country] => US
[patent_app_date] => 2024-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 0
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 217
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441086
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/441086 | Systems and processes to screen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 2019 (COVID-19) | Feb 13, 2024 | Issued |
Array
(
[id] => 20742961
[patent_doc_number] => 12642843
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-02
[patent_title] => Contraceptive vaccine based on the sperm-associated protein catsper
[patent_app_type] => utility
[patent_app_number] => 18/437608
[patent_app_country] => US
[patent_app_date] => 2024-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 0
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437608
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/437608 | Contraceptive vaccine based on the sperm-associated protein catsper | Feb 8, 2024 | Issued |
Array
(
[id] => 19359354
[patent_doc_number] => 20240261388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates
[patent_app_type] => utility
[patent_app_number] => 18/407958
[patent_app_country] => US
[patent_app_date] => 2024-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33436
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407958
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/407958 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | Jan 8, 2024 | Pending |
Array
(
[id] => 19541789
[patent_doc_number] => 20240358825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => Novel Adjuvant Compositions
[patent_app_type] => utility
[patent_app_number] => 18/406869
[patent_app_country] => US
[patent_app_date] => 2024-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18406869
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/406869 | Adjuvant compositions | Jan 7, 2024 | Issued |
Array
(
[id] => 19815124
[patent_doc_number] => 20250073331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => USE OF CODON DEOPTIMISATION AND OPTIMISATION TO PRODUCE A LARYNGOTRACHEITIS VIRUS-ATTENUATED VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/528294
[patent_app_country] => US
[patent_app_date] => 2023-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528294
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/528294 | USE OF CODON DEOPTIMISATION AND OPTIMISATION TO PRODUCE A LARYNGOTRACHEITIS VIRUS-ATTENUATED VACCINE | Dec 3, 2023 | Pending |
Array
(
[id] => 19156137
[patent_doc_number] => 20240148844
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => APPARATUS FOR DETERMINING ADMINISTRATION FORM OF A COMPOSITION OF AN ENGINEERED VIRUS-BASED NANOPARTICLE FOR A TREATMENT OF AN AUTOIMMUNE CONDITION
[patent_app_type] => utility
[patent_app_number] => 18/386007
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386007
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/386007 | Apparatus for determining administration form of a composition of an engineered virus-based nanoparticle for a treatment of an autoimmune condition | Oct 31, 2023 | Issued |
Array
(
[id] => 18970462
[patent_doc_number] => 20240050554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/491193
[patent_app_country] => US
[patent_app_date] => 2023-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32774
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491193
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/491193 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | Oct 19, 2023 | Issued |